We're Heading to Brussels! 4Dcell Selected for EIC Corporate Day

Big news from Paris! We've just received word that 4Dcell has been chosen to showcase our SmartHeart cardiac testing platform at the European Innovation Council's Corporate Day.

This isn't just any industry event, it's where the most promising biotech innovations meet the pharmaceutical giants who could transform entire treatment landscapes.

Why the EIC Corporate Day Selection Matters

Being selected by the European Innovation Council represents a significant validation of everything we've been working toward. This exclusive event connects breakthrough technologies with major pharmaceutical companies, and being chosen means one of Europe's most prestigious innovation bodies sees the transformative potential in what we're building.

But here's what makes this moment especially significant: we're not just another biotech with a promising idea. We're addressing one of the pharmaceutical industry's most persistent and costly problems. Over 90% of drugs that show promise in preclinical trials fail in human studies, often due to cardiac toxicity that existing testing methods simply miss. That's not just a statistic, it represents billions in lost investment and, more importantly, delayed treatments for patients who desperately need them.

The Science That Makes the Difference

Our cardiac NAMs platform, anchored by our SmartHeart technology, tackles this problem head-on. Instead of relying on traditional cell cultures or animal models that don't fully capture human cardiac complexity, we've created something different: a system that mimics human cardiac tissue behavior with unprecedented precision.

"Our mission is to transform drug development by making it faster, safer, and more ethical through simple models that reproduce biological complexity," explains 4Dcell CEO, Cyril Cerveau.

"Developing NAMs to accelerate drug market entry for our industrial partners is our daily challenge, and that's exactly what we are striving to achieve with our cardiac organoid technology, SmartHeart."

What sets our platform apart isn't just one breakthrough, it's the combination of cutting-edge tissue engineering, advanced analytics, and physiologically relevant models working together. This creates something the industry has been searching for: a bridge between traditional laboratory testing and human physiology.

Our Chief Technology Officer, Dr. Rita S. Rodrigues Ribeiro, puts it this way:

"What makes our platform truly valuable is its ability to bridge the gap between traditional in vitro testing and human physiology, providing the pharmaceutical industry with the predictive power they need to make better, faster decisions, all while ensuring easy usability, interoperability, maturity, and high throughput."

The key word there is "predictive." Current testing methods often fail to predict cardiac toxicity that shows up in human trials. Our platform is designed to catch these issues early, when they can still be addressed rather than discovered after millions have been invested.

Validation: From Lab Bench to Real-World Impact

We're not just talking about potential, our technology is proving itself across multiple academic and industrial laboratories worldwide. Each validation study demonstrates the consistent reliability and predictive accuracy that pharmaceutical companies need to trust a new testing method.

This validation process is crucial because we're asking the industry to reconsider fundamental approaches to drug testing. That requires not just promising early results, but consistent, reproducible performance across different settings and applications.

The timing of this EIC selection couldn't be better. Several forces are converging to create an unprecedented opportunity for technologies like ours:

• Regulatory support: Both the FDA and EMA are actively encouraging the adoption of alternative testing methods, creating a favorable regulatory environment for NAMs technologies.

• Industry pressure: Pharmaceutical companies face mounting pressure from investors and stakeholders to improve success rates and reduce development timelines.

• Ethical imperatives: There's growing demand for more ethical testing methods that reduce reliance on animal testing while providing better predictive power.

What Brussels Represents

The EIC Corporate Partnership Programme connects innovative companies like ours with global leaders across healthcare and life sciences. At the Innovation Roundtable in Brussels this October 8-9, we'll be presenting directly to decision-makers from companies like Procter & Gamble, Air Liquide, Chiesi Group, and Nestlé: companies that are actively seeking exactly the kind of innovations we're developing.

"This EIC Corporate Day represents a great opportunity for 4Dcell and validates our vision of modernizing preclinical testing," says our President and Co-founder, Maël Le Berre.

"The support from the European Innovation Council will accelerate our path to market and help us deliver on our promise to make drug development more predictive."

These aren't just networking opportunities: they're potential partnerships that could accelerate the adoption of our technology across global drug development programs, potentially impacting treatment development for millions of patients worldwide.

Beyond the Showcase

While we're excited about the immediate opportunity in Brussels, our vision extends far beyond any single event or partnership. We're working toward a fundamental shift in how drug development operates: from a system where 90% failure rates are accepted as inevitable to one where predictive testing dramatically improves success rates from the start.

Every successful partnership, every validation study, every regulatory approval brings us closer to that vision. When pharmaceutical companies can make better, faster decisions about drug safety and efficacy, everyone wins: companies reduce costs and timelines, regulators have better data to work with, and patients get access to safer, more effective treatments sooner.

As we prepare for Brussels, we're more convinced than ever that the convergence of advanced tissue engineering, sophisticated modeling, and supportive regulatory frameworks creates an unprecedented opportunity to transform drug development.

The pharmaceutical industry's challenges are real and urgent. Development costs are rising, timelines are extending, and success rates remain stubbornly low. But we believe there's a better way forward: one that combines better science with better outcomes for everyone involved.

We'll be sharing more about our Brussels experience and what comes next.

For now, we're focused on making the most of this opportunity to showcase how SmartHeart and our NAMs platform can help solve one of the pharmaceutical industry's most persistent challenges.

Want to learn more about our technology and mission? Visit us at www.4dcell.com or reach out to our team at contact@4dcell.com.